Senior Venture Partner
David Collier is a Senior Venture Partner at Pandect Bioventures. He is also Chief Executive Officer of Velocity Pharmaceutical Development and Managing Director of Presidio Partners
As CEO of Velocity Pharmaceutical Development (VPD), Dr. Collier is pioneering a new business model for the development of promising drug candidates. VPD acquires the rights to individual therapeutic drug candidates and invests in their development through clinical proof-of-concept at which point VPD seeks to sell each drug asset to a major pharmaceutical company.
Collier joined Presidio Partners in 2001 to focus on investments in biotechnology companies developing drugs through clinical trials across many different therapeutic areas. Examples include Ardelyx, Bayhill Therapeutics, Arcion Therapeutics, Altus Pharmaceuticals and Auspex Pharmaceuticals.
Before joining Presidio Partners, Dr. Collier was a Managing Director at Burrill & Co., a private merchant bank focused exclusively on life science companies, where he played a leading role in the management of the company’s life science venture capital funds. Earlier in his career, Dr. Collier was Assistant Vice President at First Options of Chicago where he directed a group of traders and managed a large portfolio of futures and options. Dr. Collier holds an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School, and a B.A. in Physics from Wesleyan University.